BrainStorm Cell Therapeutics secured $2.4 million in capital during the first half of 2026 through private placements priced at a premium, aiming to support its upcoming Phase 3b ENDURANCE trial for NurOwn®, a stem cell therapy targeting ALS. The recent financings reflect increased investor confidence and help extend the company's financial runway while minimizing shareholder dilution. BrainStorm is also exploring non-dilutive funding options to cover the larger capital needs of the trial. NurOwn® is an investigational therapy designed to slow neurodegenerative disease progression by delivering neurotrophic factors directly to damaged sites, with prior Phase 3 data and regulatory designations from the FDA and EMA.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Frasers Group PLC has withheld financial guidance for the upcoming year due to uncertainty around its takeover bids for Hugo Boss and Accent Group. The retailer's full-year adjusted profit before tax fell 4% to £538 million, impacted by asset impairm...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
